Skip to main content
Premium Trial:

Request an Annual Quote

You, too, can SPEAK GENOMICS!!!


Now is the BEST time to SIGN UP for the SPEAK GENOMICS! Learning Course!

This learning course is unique, interactive, and fun. And what’s more, with our SPEAK GENOMICS! LEARNING CDs or TAPES, you can pick up this critical life sciences skill AT YOUR OWN PACE!


The SPEAK GENOMICS! class sessions, held at TROPICAL RESORTS near many leading genomics conferences will cover six months of real-world Genomics language. You’ll be ready to:

• Confidently participate in GENOMICS CONFERENCES!

• Work in GENOMICS or POST-GENOMICS business development or marketing!


• Get your face on the cover of GENOME TECHNOLOGY MAGAZINE!

First we give you a sample of the real-world types of dialogue you will encounter, then we review with a dynamic, interactive SPEAK GENOMICS! vocabulary lesson!


Dialogue: In the conference hall

Tony: Sue, how’s your pipeline?

Sue: Robust. How’s your collaboration with bIG FoldProteomix?

Tony: You know that’s proprietary.

Sue: Right. But since we have the partnership to develop an integrated solution…

Tony: Yes we do. So what have you been doing to validate your platform lately?

Sue: We’re actually already productizing the downstream applications.

Tony: I see. Hold on. My cell.

Tony: (into cell) Oh, yes, yes, yes. (to Sue) It’s my VC. Gotta go.

Sue: OK. We’ll talk later. After the presentation.



By learning and memorizing just a few hundred vocabulary words in the GENOMICS and POST-GENOMICS lexicon, you will be well on your way to GENOMICS fluency.

Pipeline: Theoretically, products that are in the works. Realistically, a fictional tube full of the waste products from the hot air that you have blown at your venture capitalists to get them to fund your operation.

Robust: It might work. As in, our technology platform is robust. Ant. exploratory, experimental, innovative. As in, our technology is innovative, experimental, i.e., we have no idea if it will ever work.

Collaboration: a) An agreement between a hapless genomics company and a giant pharma in which the genomics company conducts free or nearly free R&D for the pharmaceutical giant in hopes of one day becoming the customer/supplier; b) an agreement in which two genomics/proteomics companies or other life sciences companies cling to one another to assure each other and the world that they are not going under; c) A crafty way for a genomics company to siphon revenue off of a more solvent company.

Proprietary: a) none of your business; b) we have no idea.

Partnership: See collaboration b) or c)


Integrated solution: Some of deez, some of doz, some of deez, some of doz …

Validate: Manufacture some hard data PDQ to show that your company and its products aren’t a total joke.

Platform: In the case of most startup companies, an overturned cardboard box upon which a phone, a sketch of a business plan, and an assortment of business cards are placed. In more mature companies, a collection of so-called “technologies” that are meant to work together but often do not.

Productize Downstream applications: a) An entirely meaningless term employed to stall for time. Similar to “Well then,” “ So,” in English; “Bon!” in French. b) somehow get something out of a completely experimental, exploratory (see above) technique.

Cell: a) a phone, not the basic unit of life

VC: a) God b) Mommy/Daddy c) Satan

Presentation: A ritual that occurs in a darkened, slightly freezing hotel ballroom in which first a computer malfunctions, then a series of PowerPoint slides accompany a few feeble jokes and a somewhat melodic lullaby of somnolence-producing numeric recitations.

— by Marian Moser Jones

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.